

REMARKS

The examiner's restriction requirement is based on original claims 1-18 which applicants intended to replace in their preliminary amendment with new claims 1-17. The present amendment cancels original claims 1-18 and replaces these with new claims 19-35, substantially the same as previously submitted claims 1-17.

Applicants respectfully elect Group I as defined by the examiner, with traverse, and request that present claims 19-35 be considered together in the present application. New claims 19-28 are directed to a process for identifying and selecting compounds for the treatment of cerebrovascular disorders, and new claims 29-35 are drawn to methods of treating these disorders with the identified and selected compounds. The processes share a special technical feature in that each involves the isolation or use of compounds which selectively bind to 5-HT5 receptors.

In view of the foregoing amendments and remarks, applicants consider that the rejections of record have been obviated and respectfully solicit passage of the application to issue.

**A check in the amount of \$110.00 is attached to cover the required one month extension fee.**

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,  
KEIL & WEINKAUF



David C. Liechty  
Reg. No. 48,692

1350 Connecticut Ave., N.W.  
Washington, D.C. 20036  
(202)659-0100

DCL/kas